Cartesian Therapeutics
RNAC
59 hedge funds and large institutions have $105M invested in Cartesian Therapeutics in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 23 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 1.63% → 1.53% (-0.09%)
2% less capital invested
Capital invested by funds: $107M → $105M (-$2.37M)
6% less funds holding
Funds holding: 63 → 59 (-4)
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.67M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.19M |
| 3 |
SRF
Silver Rock Financial
Los Angeles,
California
|
+$646K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$475K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.8M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.24M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.8M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.75M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$982K |
RNAC Hedge Fund Activity: Q1 2018 in Review
59 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2018, worth a combined $105M — down 2.2% from $107M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RNAC and 8 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 17 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.67M. The largest seller was Millennium Management, exiting entirely with an estimated $2.8M sold.
- 59 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2018, down from 63 in Q4 2017.
- Funds reported $105M of Cartesian Therapeutics stock for Q1 2018, down 2.2% quarter-over-quarter.
- 8 funds opened new Cartesian Therapeutics positions in Q1 2018 and 12 closed out, a net change of -4 holders.
- The largest Cartesian Therapeutics buyer in Q1 2018 was JP Morgan Chase, an estimated $1.67M added.
- The largest Cartesian Therapeutics seller in Q1 2018 was Millennium Management, an estimated $2.8M sold.
Based on aggregated 13F filings for Q1 2018.